Milan, Italy – 4 April 2025. Women who have experienced pre-eclampsia have accelerated accumulation of cardiovascular (CV) risk factors compared with women who had pregnancies without pre-eclampsia according to research presented today at ESC Preventive Cardiology 2025,1 a scientific congress of the European Society of Cardiology (ESC).
Pre-eclampsia typically affects 2−5% of pregnant women and is broadly defined as the development of hypertension and high protein levels in the urine of a woman with previously normal blood pressure.2 In addition to the short-term risk to foetal and maternal health, pre-eclampsia is associated with an approximately doubled risk of cardiovascular disease (CVD) and stroke.3
“Despite the known long-term risks after pre-eclampsia, guidelines do not include specific recommendations on the necessity, timing and frequency of systematic CV assessment, which is likely due to a lack of empirical data,” said study author Emma Janssen from the Maastricht University Medical Centre, Netherlands, who continued: “As part of the Queen of Hearts study, we aimed to investigate the long-term prevalence of CV risk factors in women who experienced pre-eclampsia compared with normotensive pregnancies with no increased blood pressure to help guide proactive assessment, which in turn, may lead to more timely implementation of preventive strategies.”
In this retrospective cohort study conducted in Netherlands, data were collected from adult women with a history of pre-eclampsia (within a postpartum interval of 0.5–30 years) and from healthy women with a history of uncomplicated normotensive pregnancies. Cross-sectional postpartum assessment included medical history and physical examination, 30-minute blood pressure measurements, blood and 24-hour urine sampling, vascular function evaluation, electrocardiography and echocardiography.
A total of 1,040 women after pre-eclampsia and 518 women after normotensive pregnancies were included. The researchers found higher rates of hypertension, diabetes mellitus and hypercholesterolaemia, either individually or combined, after pre-eclampsia than after normotensive pregnancies (adjusted hazard ratio 2.6; 95% confidence interval 2.1–3.2). These risk factors occurred, on average, 8 years earlier in the pre-eclampsia group (39±9 years) compared with the normotensive group (47±8 years). In addition, the prevalence of hypertension increased more steeply with ageing after pre-eclampsia than after normotensive pregnancies (p for interaction=0.044). In women after pre-eclampsia from the age of 35 years onwards, hypertension reached the CVD risk cut-off (prevalence ≥10%) that is deemed sufficiently high to warrant systematic CVD risk assessment.4
Mrs Janssen summarised the findings: “In women who have experienced pre-eclampsia, CV risk factors occur almost a decade early, predominantly, but not exclusively, due to the premature and accelerated development of hypertension. Systematic CV risk assessment is warranted from 35 years of age and should be repeated regularly, at least every 5 years, to enable these women to receive appropriate preventive measures to reduce their high risk of CVD and potential sequelae.”
Dr. Chahinda Ghossein-Doha from the Erasmus University Medical Centre, Rotterdam, Netherlands, who is the principal investigator of the Queen of Hearts study concluded: “After their pre-eclampsia is managed, these women often fall through the net, without being referred for specialised follow-up. We need to be monitoring these young women regularly to detect any increase in risk factors in a period of their life when such an accumulation may be unexpected. For women after pre-eclampsia, taking steps to lead a heart-healthy lifestyle is important, as is discussing formal CV risk assessments with a healthcare professional.”
This research was presented during a session on the life-long protection of the female heart at ESC Preventive Cardiology 2025.1 Dr. Ghossein-Doha will also present data from the Queen of Hearts study at a Late Breaking session at the congress.5 Contrary to common belief, CVD kills more women than men, accounting for 37% of all deaths in women in EU member countries.6
ENDS
ESC Press Office
Email: press@escardio.org
Follow us on X @ESCardioNews
Funding: This project was partially supported by the Dutch Heart Foundation (grant number 2013T084, Queen of Hearts study).
Disclosures: Emma Janssen and Chahinda Ghossein-Doha have no disclosures to report.
References and notes:
1‘Evaluation of the age-related prevalence of cardiovascular risk factors to guide systematic long-term follow-up after preeclampsia’ will be presented at Protecting the female heart life-long on 4 April at 10:30 to 11:15 CET on the Open Stage.
2Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145 Suppl 1:1–33.
3Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020:371:m3502.
4McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912–4018.
5‘Queen of Hearts study’ will be presented at Late breaking science on managing cardiovascular risk on 4 April at 12:45 to 13:45 CET in room Tosca.
6EU 27 Cardiovascular Realities 2025, ESC Atlas of Cardiology. Available at: https://www.escardio.org/Research/ESC-Atlas-of-cardiology
About the European Society of Cardiology
The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.
About the European Association of Preventive Cardiology
The European Association of Preventive Cardiology (EAPC) is a branch of the ESC. Its mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
About ESC Preventive Cardiology #ESCPrev2025
ESC Preventive Cardiology, formerly EuroPrevent, is the leading international congress on preventive cardiology and the annual congress of the European Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC).
Information for journalists about registration for ESC Preventive Cardiology 2025
ESC Preventive Cardiology 2025 takes place from 3 to 5 April at Allianz MiCo, Milan, Italy. Explore the scientific programme
-
Free registration applies to accredited press.
-
Credentials: A valid press card or appropriate letter of assignment with proof of three recent published articles. Read the ESC media and embargo policy.
-
The ESC Press Office will verify the documents and confirm by email that your press accreditation is valid.
-
The ESC Press Office decision is final regarding all press registration requests.